

## Preliminary program

## Self-paced learning package: Available from Friday 7 August 2023

Topic and presenters	Learning objectives
<p><b>Governance, practical tips and getting started</b></p> <p><b>Hayley Vasileff</b>, <i>Team Leader Pharmacist - Haematology and Oncology, SA Pharmacy, Women's and Children's Hospital, Adelaide, SA</i></p> <p><b>John Coutsouvelis</b>, <i>Senior Clinical Pharmacist, Alfred Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Discuss the responsibilities, policies and procedures that promote safe and quality care for patients with cancer</li> <li>• Outline anti-cancer therapy resources that are available for pharmacists</li> <li>• Describe the process of ordering, checking, manufacturing and administering chemotherapy</li> <li>• Outline the required steps to check a chemotherapy order</li> <li>• Describe the main components of blood and the dysfunction that leads to malignancy</li> </ul>
<p><b>Pharmacology and toxicities of haematological anti-cancer therapies</b></p> <p><b>Amanda Tey</b>, <i>Special Medicine Team Leader &amp; Senior Haematology Pharmacist, Monash Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Describe the main components of blood and the dysfunction that leads to malignancy</li> <li>• List common toxicities of different ant-cancer therapies</li> </ul>
<p><b>Lymphoma</b></p> <p><b>Dr Nick Murphy</b>, <i>Consultant Haematologist, Royal Hobart Hospital, Hobart, Tas</i></p>	<ul style="list-style-type: none"> <li>• Describe the main components of blood and the dysfunction that leads to malignancy</li> <li>• Outline the most common types of lymphoma including Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukaemia, Hodgkin Lymphoma</li> <li>• Outline common first line treatment options for lymphoma</li> </ul>
<p><b>Multiple myeloma</b></p> <p><b>Tristan Hughes</b>, <i>Specialist Pharmacist: Oncology and Haematology, Royal Hobart Hospital, Hobart, Tas</i></p>	<ul style="list-style-type: none"> <li>• Summarise the pathophysiology and staging of multiple myeloma (MM)</li> <li>• Summarise the most common presenting symptoms of MM according to the acronym CRAB</li> <li>• Describe the common therapies used in the treatment of myeloma</li> <li>• Outline common adverse effects associated with proteasome inhibitors, dexamethasone, cyclophosphamide, immunomodulating drugs and daratumumab</li> <li>• Describe common first-line combinations of the above therapies</li> </ul>
<p><b>Coagulation and thrombosis</b></p> <p><b>Hadley Bortz</b>, <i>Senior Pharmacist - Anticoagulation Stewardship / HTH, Alfred Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Explain the pathophysiology of developing cancer associated thrombosis</li> <li>• Determine which patients are at high risk for cancer associated thrombosis and need thromboprophylaxis</li> <li>• Describe recommendations for the management of cancer associated thrombosis</li> </ul>

	<ul style="list-style-type: none"> <li>Describe the potential role of Direct Oral Anti-Coagulants (DOACs) in cancer associated thrombosis</li> </ul>
<p><b>Supportive care</b></p> <p><b>Shevon Fernando</b>, <i>Senior Haematology Pharmacist, Alfred Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>Classify common haematology cancer therapies according to emetogenic potential and recommend appropriate anti-emetic therapy</li> <li>Recognise risk factors for tumour lysis syndrome in lymphoma and myeloma and describe appropriate prevention and treatment strategies.</li> <li>Describe the role of growth factor support in common regimens used for the treatment of lymphoma and myeloma</li> <li>Overview the role of PPIs in oral hygiene in haematology patients</li> </ul>
<p><b>Infections in the immunocompromised</b></p> <p><b>Dr Claire Dendle</b>, <i>Infectious Diseases Physician; Director Infection and Immunity Service; Director of Physician Education, Monash Health, Melbourne, Vic</i></p> <p><b>Phil Selby</b>, <i>Specialist Clinical Pharmacist – Haematology, Royal Adelaide Hospital, SA Pharmacy, SA Health, Adelaide, SA</i></p>	<ul style="list-style-type: none"> <li>Recognise common risk factors for PJP, HSV/VZV and IFI infections</li> <li>Outline common treatment regimens and haematological malignancies that carry a higher risk of PJP/HSV/VZV/invasive fungal infection</li> <li>Describe appropriate management strategies for the prevention of PJP, HSV/VZV and IFI</li> </ul>

# FOUNDATION SEMINAR IN HAEMATOLOGY

## Preliminary program

All times listed are in AEDT

Saturday 2<sup>nd</sup> September 2023

Time (AEDT)	Session
0850-0855	Online login available
0855-0900	<b>Welcome, introduction, housekeeping</b> <i>Shevon Fernando</i>
0900-0940	<b>Review of self-paced learning package material and Q&amp;A</b> <i>Shevon Fernando</i>
0940-0950	<b>Case session overview and introduction</b> <i>Shevon Fernando</i>
0950-1120	<b>Case session 1 (case #1 and #2)</b> <b>Case 1:</b> <i>Amanda Tey, Shevon Fernando, Jackson Truong, Philip Selby, Emily Harding, Tristan Hughes</i> <b>Case 2:</b> <i>Amanda Tey, Shevon Fernando, Jackson Truong, Philip Selby, Emily Harding, Tristan Hughes, Philomina Banahane</i>
1120-1140	<b>Break</b>
1140-1230	<b>Case session 2 (case #3)</b> <b>Case 3:</b> <i>Amanda Tey, Shevon Fernando, Jackson Truong, Philip Selby, Emily Harding, Tristan Hughes, Philomina Banahane</i>
1230-1300	<b>Recap and Q&amp;A</b>
1300-1330	<b>Break</b>
1330-1530	<b>Case session 3 (case #4 and case #5)</b> <b>Case 4:</b> <i>Amanda Tey, Shevon Fernando, Jackson Truong, Philip Selby, Emily Harding, Tristan Hughes, Philomina Banahane</i> <b>Case 5:</b> <i>Amanda Tey, Shevon Fernando, Jackson Truong, Philip Selby, Emily Harding, Tristan Hughes, Philomina Banahane</i>
1530-1550	<b>Break</b>
1550-1650	<b>Recap and Q&amp;A with competition quiz</b> <i>Shevon Fernando</i>
1650	<b>Close of live virtual seminar</b>

**Please note: presentation recordings from the live virtual seminar will not be available.**